Fusi F - Search Results

1

Nitrobenzoxadiazole derivatives of the rat selective toxicant norbormide as fluorescent probes for live cell imaging.

Wang ZL, Li FF, Quach R, Ferrarese A, Forgiarini A, Ferrari M, D'Amore C, Bova S, Orso G, Fusi F, Saponara S, Hopkins B, Brimble MA, Rennison D. Wang ZL, et al. Among authors: fusi f. Bioorg Med Chem. 2022 Apr 1;59:116670. doi: 10.1016/j.bmc.2022.116670. Epub 2022 Feb 17. Bioorg Med Chem. 2022. PMID: 35202967

2

Effects of some sterically hindered phenols on whole-cell Ca(2+) current of guinea-pig gastric fundus smooth muscle cells.

Fusi F, Saponara S, Gagov H, Sgaragli G. Fusi F, et al. Br J Pharmacol. 2001 Mar;132(6):1326-32. doi: 10.1038/sj.bjp.0703935. Br J Pharmacol. 2001. PMID: 11250884 Free PMC article.

3

2,5-Di-t-butyl-1,4-benzohydroquinone (BHQ) inhibits vascular L-type Ca(2+) channel via superoxide anion generation.

Fusi F, Saponara S, Gagov H, Sgaragli G. Fusi F, et al. Br J Pharmacol. 2001 Aug;133(7):988-96. doi: 10.1038/sj.bjp.0704183. Br J Pharmacol. 2001. PMID: 11487507 Free PMC article.

4

Quercetin as a novel activator of L-type Ca(2+) channels in rat tail artery smooth muscle cells.

Saponara S, Sgaragli G, Fusi F. Saponara S, et al. Among authors: fusi f. Br J Pharmacol. 2002 Apr;135(7):1819-27. doi: 10.1038/sj.bjp.0704631. Br J Pharmacol. 2002. PMID: 11934824 Free PMC article.

5

Ca(2+) entry blocking and contractility promoting actions of norbormide in single rat caudal artery myocytes.

Fusi F, Saponara S, Sgaragli G, Cargnelli G, Bova S. Fusi F, et al. Br J Pharmacol. 2002 Oct;137(3):323-8. doi: 10.1038/sj.bjp.0704877. Br J Pharmacol. 2002. PMID: 12237251 Free PMC article.

6

Effects of quercetin and rutin on vascular preparations: a comparison between mechanical and electrophysiological phenomena.

Fusi F, Saponara S, Pessina F, Gorelli B, Sgaragli G. Fusi F, et al. Eur J Nutr. 2003 Jan;42(1):10-7. doi: 10.1007/s00394-003-0395-5. Eur J Nutr. 2003. PMID: 12594537

7

Relaxant and Ca2+ channel blocking properties of norbormide on rat non-vascular smooth muscles.

Bova S, Cavalli M, Cima L, Luciani S, Saponara S, Sgaragli G, Cargnelli G, Fusi F. Bova S, et al. Among authors: fusi f. Eur J Pharmacol. 2003 Jun 6;470(3):185-91. doi: 10.1016/s0014-2999(03)01797-7. Eur J Pharmacol. 2003. PMID: 12798957

8

L-type Ca2+ channels activation and contraction elicited by myricetin on vascular smooth muscles.

Fusi F, Saponara S, Frosini M, Gorelli B, Sgaragli G. Fusi F, et al. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):470-8. doi: 10.1007/s00210-003-0836-y. Epub 2003 Nov 15. Naunyn Schmiedebergs Arch Pharmacol. 2003. PMID: 14618297

9

3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility.

Saponara S, Kawase M, Shah A, Motohashi N, Molnar J, Ugocsai K, Sgaragli G, Fusi F. Saponara S, et al. Among authors: fusi f. Br J Pharmacol. 2004 Feb;141(3):415-22. doi: 10.1038/sj.bjp.0705635. Epub 2004 Jan 12. Br J Pharmacol. 2004. PMID: 14718255 Free PMC article.

10

Mechanism of myricetin stimulation of vascular L-type Ca2+ current.

Fusi F, Sgaragli G, Saponara S. Fusi F, et al. J Pharmacol Exp Ther. 2005 May;313(2):790-7. doi: 10.1124/jpet.104.080135. Epub 2005 Jan 21. J Pharmacol Exp Ther. 2005. PMID: 15665142

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

250 results

Search Page

Filters